Cost analysis of COPD exacerbations and cardiovascular events in SUMMIT.

Abstract

OBJECTIVES:

The Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial compared the efficacy of once-daily fluticasone furoate/vilanterol (FF/VI) with placebo, FF monotherapy, and VI monotherapy on mortality in patients with moderate chronic obstructive pulmonary disease (COPD) and a history/increased risk of cardiovascular (CV) disease. We conducted a post hoc economic analysis using data from SUMMIT to evaluate the economic benefits of treating these patients with COPD and CV risk.

STUDY DESIGN:

Patients (aged 40-80 years, with ≥10 pack-years' smoking history and a risk of CV events) were randomized (1:1:1:1) to receive placebo, FF 100 mcg, VI 25 mcg, or FF/VI 100 mcg/25 mcg.

METHODS:

This was a post hoc economic analysis to assess the rates and associated costs of the composite end point (acute COPD exacerbations and revascularization/CV composite events) in the SUMMIT trial from a US healthcare payer perspective.

RESULTS:

Overall, 16,485 patients were evaluated; of these, 5246 (31.8%) experienced an on-treatment composite end point event (28.5% experienced a COPD exacerbation, 4.2% experienced a CV event, and 2.0% underwent a revascularization procedure). The mean estimated 1-year on-treatment combined end point cost was highest for placebo and lowest for FF/VI ($4220 vs $3482, respectively). The reductions in cost versus placebo were significant for all active treatments (P <.0001). The likelihood of experiencing an on-treatment combined end point event was lower for patients treated with FF/VI versus placebo (hazard ratio, 0.81; P <.001).

CONCLUSIONS:

One-year combined end point event costs were significantly lower for all active treatments versus placebo. Clinicians and payers may be able decrease costs by effectively managing patients' COPD in those with CV risk.

• Authors: Richard H Stanford, Anna D Coutinho, Michael Eaddy, Binglin Yue, Michael Bogart
• Journal: The American journal of managed care (Am J Manag Care) Vol. 25 Issue 11 Pg. e320-e325 (11 01 2019) ISSN: 1936-2692 [Electronic] United States
• PMID: 31747236 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Androstadienes
• Benzyl Alcohols
• Chlorobenzenes
• Drug Combinations
• Glucocorticoids
• vilanterol
• fluticasone furoate

Topics

• Adult
• Aged
• Aged, 80 and over
• Androstadienes (economics)
• Benzyl Alcohols (economics)
• Cardiovascular Diseases (epidemiology)
• Chlorobenzenes (economics)
• Costs and Cost Analysis
• Drug Combinations
• Female
• Glucocorticoids (economics)
• Humans
• Male
• Middle Aged
• Prospective Studies
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• United States (epidemiology)